We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$27.2B
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.16%
1 Year Est. Return
+43.16%
3 Year Est. Return
+177.72%
5 Year Est. Return
+262.7%
10 Year Est. Return
+1,121.27%
AUM
$22.5B
AUM Growth
+$1.93B
(+9.4%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
26.61%
Holding
1,346
New
164
Increased
337
Reduced
605
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$426M |
| 2 |
Deere & Co
DE
|
+$212M |
| 3 |
NVIDIA
NVDA
|
+$149M |
| 4 |
W.W. Grainger
GWW
|
+$140M |
| 5 |
Netflix
NFLX
|
+$135M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$196M |
| 2 |
Home Depot
HD
|
+$189M |
| 3 |
Gilead Sciences
GILD
|
+$145M |
| 4 |
Oracle
ORCL
|
+$145M |
| 5 |
Microsoft
MSFT
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.24% |
| 2 | Financials | 13.5% |
| 3 | Healthcare | 12.02% |
| 4 | Consumer Discretionary | 11.94% |
| 5 | Industrials | 11.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Regenxbio
RGNX
$704M
| $368K | ﹤0.01% |
19,479
-14,781
| -43% | -$327K |
|
|
NARI
952
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $368K | ﹤0.01% |
5,963
-585
| -9% | -$35.1K |
|
953
Par Pacific Holdings
PARR
$4.12B
| $368K | ﹤0.01% |
12,601
-23,311
| -65% | -$623K |
|
954
Genco Shipping & Trading
GNK
$1.13B
| $363K | ﹤0.01% |
23,183
-1,120
| -5% | -$19.2K |
|
955
Northrop Grumman
NOC
$81.6B
| $362K | ﹤0.01% |
784
-46
| -6% | -$21.3K |
|
956
Astrana Health
ASTH
$1.87B
| $362K | ﹤0.01% |
9,913
-36,160
| -78% | -$1.27M |
|
|
NWLI
957
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $362K | ﹤0.01% |
1,490
-84
| -5% | -$21.9K |
|
958
Check Point Software Technologies
CHKP
$13.7B
| $360K | ﹤0.01% |
2,766
-10,494
| -79% | -$1.34M |
|
|
MORF
959
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $359K | ﹤0.01% |
9,543
-2,473
| -21% | -$91.1K |
|
960
Old Dominion Freight Line
ODFL
$44.7B
| $359K | ﹤0.01% |
2,104
-62
| -3% | -$10.4K |
|
961
EOG Resources
EOG
$74.2B
| $352K | ﹤0.01% |
3,075
-235,185
| -99% | -$28.5M |
|
962
Phreesia
PHR
$780M
| $352K | ﹤0.01% |
10,890
-757
| -6% | -$26.6K |
|
|
MRC
963
DELISTED
MRC Global
MRC
| $349K | ﹤0.01% |
+35,868
| New | +$407K |
|
964
Apogee Enterprises
APOG
$888M
| $346K | ﹤0.01% |
8,009
-205
| -2% | -$9.21K |
|
965
First Solar
FSLR
$24B
| $346K | ﹤0.01% |
1,592
-49,620
| -97% | -$9.06M |
|
966
Usana Health Sciences
USNA
$252M
| $346K | ﹤0.01% |
5,493
-600
| -10% | -$35.8K |
|
967
OptimizeRx
OPRX
$165M
| $345K | ﹤0.01% |
23,552
-600
| -2% | -$10K |
|
968
DigitalOcean
DOCN
$15.6B
| $344K | ﹤0.01% |
+8,777
| New | +$276K |
|
969
Crane NXT
CXT
$2.96B
| $343K | ﹤0.01% |
8,697
-1,354
| -13% | -$53.5K |
|
970
Sempra
SRE
$56.5B
| $343K | ﹤0.01% |
4,536
+234
| +5% | +$18K |
|
971
Palomar
PLMR
$3.37B
| $343K | ﹤0.01% |
+6,207
| New | +$333K |
|
972
Merit Medical Systems
MMSI
$5.4B
| $340K | ﹤0.01% |
4,598
-836
| -15% | -$58.7K |
|
973
BridgeBio Pharma
BBIO
$15.9B
| $339K | ﹤0.01% |
20,473
-1,427
| -7% | -$16.6K |
|
|
MPX
974
DELISTED
Marine Products Corp
MPX
| $339K | ﹤0.01% |
25,712
-420
| -2% | -$5.48K |
|
975
Brunswick
BC
$5.29B
| $339K | ﹤0.01% |
4,131
| – | – |
|
Similar funds
FDCDDQ
WP
N
PCH
VAI
Los Angeles Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Los Angeles Capital Management held 1,346 positions worth $22.5B, up 9.4% from $20.6B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Los Angeles Capital Management's Q1 2023 filing shows 164 new, 337 increased, 605 reduced and 194 closed positions. Its largest new stake was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M. The largest sale was Pfizer, an estimated $196M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.
- Los Angeles Capital Management's largest Q1 2023 buy was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M.
- Los Angeles Capital Management added most to Visa in Q1 2023, an estimated $426M increase.
- Los Angeles Capital Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $196M.
- Los Angeles Capital Management fully exited Regions Financial in Q1 2023, selling an estimated $50.4M.
- Los Angeles Capital Management's ten largest holdings make up 27% of its $22.5B portfolio in Q1 2023.
- Los Angeles Capital Management opened 164 new positions and closed 194 in Q1 2023.
- Los Angeles Capital Management's portfolio value rose 9.4% quarter-over-quarter to $22.5B.
Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.